Abstracts tagged "Biomarkers and osteoarthritis"

Abstract Number: 1978 • 2019 ACR/ARP Annual Meeting
HSP90AA1, a Chaperone-mediated Autophagy Mediator, Is a Biomarker of Joint Damage in Osteoarthritis
Irene Lorenzo-Gomez¹, Uxia Nogueira-Recalde ², Natividad Oreiro ³, Jose antonio Pinto-Tasende ⁴, Francisco J. Blanco ³ and Beatriz Carames ¹, ¹Grupo de Biología del Cartílago, Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña, Sergas, A Coruña, Spain, A Coruna, Spain, ²Grupo de Biología del Cartílago, Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña, Sergas, A Coruña, Spain, A Coruña, Spain, ³Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, España, A Coruña, Spain, ⁴Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, España, A Coruna, Spain
Background/Purpose: In osteoarthritis (OA) defects in Autophagy are evident and precede joint damage. Therefore, identifying biomarkers associated with autophagy defects could facilitate the development of…
Abstract Number: 2187 • 2017 ACR/ARHP Annual Meeting
Association of Circulating microRNAs with Prevalent and Incident Osteoarthritis in Women: The Ofely Study
Jean-Charles Rousseau¹, Marjorie Millet¹, Martine Croset¹, Elisabeth Sornay-Rendu², Olivier Borel² and Roland Chapurlat³, ¹INSERM 1033, Lyon, France, ²INSERM 1033, E. Herriot Hospital, Hospices Civils de Lyon, Lyon, France, ³INSERM 1033, University of Lyon, E. Herriot Hospital, Hospices Civils de Lyon, Lyon, France
Background/Purpose: Sensitive and specific blood biomarkers to detect the initial stages of osteoarthritis (OA) and to predict the future development of the disease are not…
Abstract Number: 1017 • 2016 ACR/ARHP Annual Meeting
Statistical Simulation Using Data from the Foundation for the National Institute of Health/Osteoarthritis Initiative Biomarkers Consortium to Evaluate the Clinical Utility of Prognostic Knee Osteoarthritis Biomarkers in Designing a Knee Osteoarthritis Clinical Trial
Sheng Feng¹, Zheng (Roger) Liu², Feng Hong¹, Jeroen Medema¹, Rajesh Kamath¹ and Marc C. Levesque¹, ¹AbbVie Bioresearch Center, Worcester, MA, ²AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA
Background/Purpose: Development of disease-modifying osteoarthritis drugs (DMOADs) for knee osteoarthritis (OA) has been challenging, partially owing to lack of prognostic biomarkers. Our objective was to…
Abstract Number: 1197 • 2016 ACR/ARHP Annual Meeting
Certain Serum Micro-RNAs Are Associated with Osteoarthritis
Jean-Charles Rousseau¹, Elisabeth Sornay-Rendu¹, Olivier Borel¹ and Roland Chapurlat², ¹INSERM UMR 1033, Lyon, France, ²Service de Rhumatologie et Pathologie Osseuse, Hôpital Edouard Herriot, INSERM UMR 1033 and Université de Lyon and Hospices Civils de Lyon, Lyon, France
Background/Purpose: Sensitive and specific blood biomarkers to detect the initial stages of osteoarthritis (OA) and to predict the future development of the disease are not…
Abstract Number: 2351 • 2016 ACR/ARHP Annual Meeting
Racial Differences in Magnetic Resonance Image-Based Three-Dimensional Bone Shape of the Knee: Data from the Osteoarthritis Initiative (OAI)
Jing-Sheng Li¹, Michael A Bowes², David T. Felson³, Philip G. Conaghan⁴, Carrie Brown⁵ and Tuhina Neogi⁶, ¹Boston University, Boston, MA, ²Imorphics Ltd, Manchester, United Kingdom, ³Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵Boston University School of Public Health, Boston, MA, ⁶Clinical Epidemiology, Boston University School of Medicine, Boston, MA
Background/Purpose: African Americans have higher prevalence and greater severity of knee osteoarthritis (OA) on radiographs compared with Caucasians. Magnetic resonance imaging (MRI)-based quantification of 3-dimensional…
Abstract Number: 1007 • 2015 ACR/ARHP Annual Meeting
Change in Semi-Quantitative Imaging Biomarkers Predicts Knee Osteoarthritis Progression: Data from the Fnih OA Biomarkers Consortium
Jamie E. Collins¹, Elena Losina², Michael C. Nevitt³, Frank W. Roemer⁴, Ali Guermazi⁴, John A. Lynch⁵, Jeffrey N. Katz², C. Kent Kwoh⁶, Joanne M. Jordan⁷, Virginia Kraus⁸ and David Hunter⁹, ¹Orthopaedic and Arthritis Center for Outcomes Research, Department of Orthopedic Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³University of California, San Francisco, San Francisco, CA, ⁴Boston University School of Medicine, Boston, MA, ⁵University of California San Francisco, San Francisco, CA, ⁶University of Arizona, Tucson, AZ, ⁷Thurston Arthritis Research Center, University of North Carolina, Chapel Hill, NC, ⁸Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC, ⁹University of Sydney, Sydney, Australia
Background/Purpose: Semi-quantitative scoring of magnetic resonance images (MRIs) is a valuable method for performing multi-feature assessment of the knee joint. The goal of this study…
Abstract Number: 1248 • 2015 ACR/ARHP Annual Meeting
Discovery of Novel Serum Biomarkers for Osteoarthritis Using Affinity Proteomics
Lucía Lourido^1,2, Burcu Ayoglu³, Juan Fernández-Tajes⁴, Frauke Henjes³, Jochen M. Schwenk³, Cristina Ruiz-Romero^1,5, Peter Nilsson³ and Francisco J. Blanco², ¹Rheumatology Division. ProteoRed-ISCIII. Proteomic Group, Inibic- C. Hospitalario Universitario A Coruña, A Coruña, Spain, ²RIER-RED de Inflamación y Enfermedades Reumáticas, INIBIC-CHUAC, A Coruña, Spain, A Coruña, Spain, ³Affinity Proteomics, SciLifeLab, School of Biotechnology, KTH - Royal Institute of Technology, Stockholm, Sweden, Stockholm, Sweden, ⁴Wellcome Trust Centre For Human Genetics, McCarthy’s Group, University of Oxford, Roosevelt Drive, Oxford OX3 7BN, United Kingdom, Oxford, England, ⁵CIBER-BBN Instituto de Salud Carlos III, INIBIC-CHUAC, A Coruña, Spain, A Coruña, Spain
Background/Purpose: Osteoarthritis (OA) is the most common rheumatic disease. Despite active research in the OA biomarker field, no single protein is sufficiently reliable for its…
Abstract Number: 2398 • 2015 ACR/ARHP Annual Meeting
Microrna Biomarker Signature in Osteoarthritis
L. A. Bennett¹, T. Coleman¹, W. Ferrell¹, J. Lockhart², C. Huesa¹, L. Dunning¹, B. Jones³, M. Blyth³, I. B. McInnes¹, M. Kurowska-Stolarska¹ and C. S. Goodyear¹, ¹Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary Medicine and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ²The Centre for Musculoskeletal Science, University of the West of Scotland, Paisley, United Kingdom, ³Orthopedic Research Group, Orthopedic Department, Glasgow Royal Infirmary, Glasgow, United Kingdom
Background/Purpose: Our current understanding of osteoarthritis (OA) comes mainly from late stage disease and this is partly due to when patients present with symptoms. It…
Abstract Number: 2399 • 2015 ACR/ARHP Annual Meeting
Baseline Fibulin3 Concentrations Are Associated with Incidence of Clinical Knee OA after 30 Months in Overweight and Obese Women
Jos Runhaar^1,2, Christelle Sanchez^3,4, Sébastien Taralla⁵, Yves Henrotin^4,6 and Sebastia Bierma-Zeinstra^2,7, ¹PO Box 2040, Erasmus MC University Medical Center Rotterdam, Department of General Practice, Rotterdam, Netherlands, ²D-BOARD Consortium, an European Committee FP7 project, Rotterdam, Netherlands, ³University of Liège, Bone and Cartilage Research Unit, Arthropôle Liege, University of Liege, Liege, Belgium, ⁴D-BOARD Consortium, an European Committee FP7 project, Liege, Belgium, ⁵Artialis SA, Liege, Belgium, ⁶Bone and Cartilage Research Unit, Arthropôle Liege, University of Liege, Liege, Belgium, ⁷Erasmus MC University Medical Center Rotterdam, Department of General Practice, Rotterdam, Netherlands
Background/Purpose: Fibulin3 is highly expressed in osteoarthritic cartilage and inhibits angiogenesis and chondrocyte differentiation. It has been demonstrated to interact with the tissue inhibitor of…
Abstract Number: 210 • 2014 ACR/ARHP Annual Meeting
Preliminary Assessment of Predictive Validity of Cartilage Thickness MRI Biomarkers in Knee OA – the Fnih OA Biomarkers Consortium
David J. Hunter¹, Jamie E. Collins², Michael C. Nevitt³, John A. Lynch⁴, Virginia B. Kraus⁵, Jeffrey N. Katz⁶, Elena Losina², Frank Roemer⁷, Ali Guermazi⁸, Wolfgang Wirth⁹ and Felix Eckstein¹⁰, ¹Rheumatology, Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, Australia, ²Orthopaedic and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA, ³Epidemiology & Biostatistics, UCSF (University of California, San Francisco), San Francisco, CA, ⁴Department of Epidemiology and Biostatistics, University of California at San Francisco, San Francisco, CA, ⁵Medicine/Rheumatology, Duke University Medical Center, Durham, NC, ⁶Rheumatology and Orthopedics, Brigham and Women's Hospital, Boston, MA, ⁷Klinikum Augsburg, Augsburg, Germany, ⁸Radiology, Boston University School of Medicine, Boston, MA, ⁹Strubergasse 21, Paracelsus Medical University, Salzburg, Austria, ¹⁰Anatomy & Musculoskeletal Research, Paracelsus Medical University, Salzburg, Austria
Background/Purpose We sought to investigate if cartilage thickness change over 24 months predicts clinically relevant progression (radiographic and/or symptomatic) in knee OA over a 48…
Abstract Number: 2757 • 2013 ACR/ARHP Annual Meeting
Metabolomics For The Identification Of Urinary Biomarkers In Knee Osteoarthritis Progression
Puja Saxena¹, Richard F. Loeser², Wimal Pathmasiri³, Susan Sumner³, Daniel Beavers⁴, David J. Hunter⁵ and Stephen P. Messier⁶, ¹Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, ²Section Of Molecular Medicine, Wake Forest School of Medicine, Winston-Salem, NC, ³Systems and Translational Sciences, NIH Eastern Regional Comprehensive Metabolomics Resource Core, Research Triangle Park, NC, ⁴Department of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC, ⁵Rheumatology, Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, Australia, ⁶Department of Health and Exercise Science, Wake Forest University, Winston-Salem, NC
Background/Purpose: Obesity is an important risk factor for knee OA, not only due to effects of excess adipose tissue on joint loading, but also due…
Abstract Number: 1134 • 2013 ACR/ARHP Annual Meeting
More Evidence For Breaking The ‘law Of valgus’: Imaging Evidence For Higher Prevalence and Volume Of Bone Marrow Lesions In The Medial Patellofemoral Joint
Charles Ratzlaff¹ and Jeffrey W. Duryea², ¹Harvard Medical School / Brigham and Women's Hospital, Boston, MA, ²Radiology, Brigham and Women's Hospital, Boston, MA
Background/Purpose : We recently developed an efficient semi-automated measure of tibial and femoral BML volume and validated it against the Whole-Organ Magnetic Resonance Imaging Score…
Abstract Number: 735 • 2012 ACR/ARHP Annual Meeting
Mass Spectrometry Assays of Plasma Biomarkers to Predict Radiographic Progression of Knee Osteoarthritis
Susan Y. Ritter¹, William M. Reichmann², Jamie E. Collins³, Alejandra Garces⁴, Bryan Krastins⁴, David Sarracino⁴, Mary Lopez⁴, Elena Losina³ and Antonios O. Aliprantis⁵, ¹Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Orthopedics, Brigham and Women's Hospital, Boston, MA, ³Orthopaedic and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA, ⁴Thermo Fisher Scientific BRIMS Center, Cambridge, MA, ⁵Rheumatology/Immunology, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Biomarkers to identify osteoarthritis (OA) patients at risk for disease progression are needed. Recently, we performed a proteomic analysis of knee synovial fluid from…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].